# MASSACHUSETTS GENERAL HOSPITAL: Targeting CDK2 in CDK4/6 inhibitor-resistant HR-positive/HER2-negative breast cancer

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | MASSACHUSETTS GENERAL HOSPITAL |
| Location | BOSTON, MA |
| Project | Targeting CDK2 in CDK4/6 inhibitor-resistant HR-positive/HER2-negative breast cancer |
| Project number | 1R01CA316243-01 |
| Mechanism | R01 |
| Institute | National Cancer Institute |
| Award | $660,843 |
| Awarded | 2026-09-09 |
| Project period | 2026-09-09 to 2031-08-31 |
| UEI | FLJ7DQKLL226 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11427743). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.